Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.

Journal of acquired immune deficiency syndromes (1999) - 15 Apr 2015

Rodriguez-Torres Maribel, Gaggar Anuj, Shen Gong, Kirby Brian, Svarovskaia Evguenia, Brainard Diana, Symonds William T, McHutchison John G, Gonzalez Milagros, Rodriguez-Orengo Jose

Abstract excerpt

BACKGROUND: Chronic hepatitis C virus (HCV) infection is a major cause of morbidity and mortality among HIV-infected patients. Sofosbuvir is a first-in-class HCV NS5B inhibitor with potent pan-genotypic antiviral activity. We report a 2-part study that assessed the efficacy and safety of sofosbuvir in HCV/HIV-coinfected patients. Part A examined potential drug interactions between sofosbuvir and antiretrovirals...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Retroviral Agents
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Ribavirin

Share to Sofosbuvir

Share to Uridine Monophosphate

Share to Viral Load

Source

Identifiers

PMID: 25622055
DOI: 10.1097/QAI.0000000000000516

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.PMID 25622055Read ↗

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.Semantic proximity Read ↗

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.Semantic proximity Read ↗

Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.Semantic proximity Read ↗

Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.Semantic proximity Read ↗

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.Semantic proximity Read ↗

Sofosbuvir for previously untreated chronic hepatitis C infection.Semantic proximity Read ↗

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.Semantic proximity Read ↗

Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.Semantic proximity Read ↗

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.Semantic proximity Read ↗

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infectionSemantic proximity Read ↗

Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection.Semantic proximity Read ↗

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.